Methods and compositions for treatment of cancer
AssigneeCFD Research Corporation
InventorAnuj Singhal
Life of this patent
Estimating the term…
Abstract
In an aspect, the disclosure pertains to inhibitors of ANGPTL4; synthesis methods for making disclosed compounds; pharmaceutical compositions comprising disclosed compounds; methods of treating disorders of uncontrolled cellular proliferation, e.g., a cancer; and methods of treating a disease associated with an ANGPTL4 dysfunction using disclosed compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Claims32
A compound having a structure represented by a formula:
- wherein L1 is optionally present, and when present, L1 is selected from —NH—, —CH2—, —(CH2)2—, —(CH2)3—, —(CH2)4—, and —(CH2)5—;
- wherein L2 is optionally present, and when present, L2 is selected from —CH2—, —(CH2)2—, —(CH2)3—, —(CH2)4—, and —(CH2)5—;
- wherein each of Q1 and Q2 is independently selected from —CH— and N, provided that Q2 and L1 are not simultaneously N;
- wherein W is selected from —O—, —S—, —CH2—, or —NH—;
- wherein Y is selected from —CH— or N;
- wherein Z is selected from O, S, halogen, hydroxyl, cyano, —NH2, and —SF5, and wherein the dashed line represents an optional bond as required to maintain standard valency;
- wherein each of R1, R2, R3, and R4 is independently selected from hydrogen, halogen, cyano, hydroxyl, —NH2, —SF5, —O(C1-C6 alkyl), —S(C1-C6 alkyl), C1-C6 haloalkyl, and C1-C6 hydroxyalkyl;
- wherein R5 is selected from hydrogen and C1-C6 alkyl;
- and
- wherein each of R6a, R6b, R7a, R7b, R8a, R8b, R9a, and R9b is independently selected from hydrogen, halogen, cyano, hydroxyl, —NH2, —SF5, —O(C1-C6 alkyl), —S(C1-C6 alkyl), C1-C6 haloalkyl, and C1-C6 hydroxyalkyl;
- or a pharmaceutically acceptable salt thereof;
- provided that the compound is not:
A compound having a structure represented by a formula:
- wherein L3 is optionally present, and when present, L3 is selected from —NH—, —CH2—, —(CH2)2—, —(CH2)3—, —(CH2)4—, and —(CH2)5—;
- wherein L4 is optionally present, and when present, L4 is selected from —CH2—, —(CH2)2—, —(CH2)3—, —(CH2)4—, and —(CH2)5—;
- wherein L5 is optionally present, and when present, L5 is selected from —CH2—, —(CH2)2—, —(CH2)3—, —(CH2)4—, and —(CH2)5—;
- wherein each of Q3 and Q4 is independently selected from —CH— and N, provided that Q4 and L3 are not simultaneously N;
- wherein each of A1 and A2 is independently selected from —N— or —CH—;
- wherein each of R21, R22, R23, and R24 is independently selected from hydrogen, halogen, cyano, hydroxyl, —NH2, —SF5, —O(C1-C6 alkyl), —S(C1-C6 alkyl), C1-C6 haloalkyl, and C1-C6 hydroxyalkyl;
- wherein each of R25, R26, R27, R28, and R29 is independently selected from hydrogen, halogen, cyano, hydroxyl, —NH2, —SF5, —O(C1-C6 alkyl), —S(C1-C6 alkyl), C1-C6 haloalkyl, and C1-C6 hydroxyalkyl;
- and
- wherein each of R210, R211, R212, R213, and R214 is independently selected from hydrogen, halogen, cyano, hydroxyl, —NH2, —SF5, —O(C1-C6 alkyl), —S(C1-C6 alkyl), C1-C6 haloalkyl, and C1-C6 hydroxyalkyl;
- or a pharmaceutically acceptable salt thereof;
- provided that the compound is not:
A compound having a structure represented by a formula:
- wherein L6 is optionally present, and when present, L6 is selected from —NH—, —CH2—, —(CH2)2—, —(CH2)3—, —(CH2)4—, and —(CH2)5—;
- wherein L7 is optionally present, and when present, L7 is selected from —CH2—, —(CH2)2—, —(CH2)3—, —(CH2)4—, and —(CH2)5—;
- wherein L8 is optionally present, and when present, L8 is selected from —CH2—, —(CH2)2—, —(CH2)3—, —(CH2)4—, and —(CH2)5—;
- wherein each of Q5 and Q6 is independently selected from —CH— and N, provided that Q6 and L6 are not simultaneously N;
- wherein each of A3 and A4 is independently selected from —N— or —CH—;
- wherein each of R31 and R32 is independently selected from hydrogen, halogen, cyano, hydroxyl, —NH2, —SF5, —O(C1-C6 alkyl), —S(C1-C6 alkyl), C1-C6 haloalkyl, and C1-C6 hydroxyalkyl;
- wherein each of R35, R36, R37, R38, and R39 is independently selected from hydrogen, halogen, cyano, hydroxyl, —NH2, —SF5, —O(C1-C6 alkyl), —S(C1-C6 alkyl), C1-C6 haloalkyl, and C1-C6 hydroxyalkyl;
- and
- wherein each of R310, R311, R312, R313, and R314 is independently selected from hydrogen, halogen, cyano, hydroxyl, —NH2, —SF5, —O(C1-C6 alkyl), —S(C1-C6 alkyl), C1-C6 haloalkyl, and C1-C6 hydroxyalkyl;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.